From: A phase 1 trial of nebulised heparin in acute lung injury
Variable | Dose | Combined n (%) | |||
---|---|---|---|---|---|
 | 50,000 U/day | 100,000 U/day | 200,000 U/day | 400,000 U/day |  |
Number of patients | 4 | 4 | 4 | 4 | 16 |
Age (years) | 57.7 ± 17.3 | 61.3 ± 14.2 | 54.3 ± 17.6 | 60.0 ± 13.0 | 58.3 ± 14.3 |
Male | 2 | 1 | 4 | 1 | 8 (50) |
Acute Physiological and Chronic Health Evaluation II score | 22.3 ± 6.0 | 21.8 ± 8.7 | 18.3 ± 10 | 20.0 ± 3.4 | 20.6 ± 7.0 |
Subcutaneous heparin | 4 | 3 | 4 | 3 | 14 (88) |
Arterial to inspired oxygen ratio (mmHg) | 159 ± 37 | 143 ± 48 | 207 ± 79 | 226 ± 75 | 183 ± 66 |
Lung compliance (ml/cmH2O) | 30 ± 7 | 19 ± 5 | 37 ± 21 | 22 ± 14 | 26 ± 14 |
Alveolar dead space fraction | 0.15 ± 0.04 | 0.3 ± 0.10 | 0.17 ± 0.07 | 0.24 ± 0.1 | 0.23 ± 0.1 |
Creatinine (μmol/l) | 80 ± 45 | 56 ± 14 | 130 ± 154 | 97 ± 45 | 91 ± 80 |
Activated partial thromboplastin time (s) | 38 ± 7 | 37 ± 6 | 44 ± 7 | 47 ± 20 | 41 ± 11 |
Thrombin clotting time (s) | 17 ± 2 | 21 ± 3 | 20 ± 10 | 19 ± 3 | 19 ± 5 |
Acute lung injury cause | Â | Â | Â | Â | Â |
   Pneumonia | 3 | 3 | 2 | 2 | 10 (63) |
   Sepsis | 0 | 0 | 1 | 1 | 2 (13) |
   Pancreatitis | 0 | 1 | 0 | 1 | 2 (13) |
   Empyema | 1 | 0 | 1 | 0 | 2 (13) |
   Aspiration | 0 | 0 | 0 | 0 | 0 |
Surgical admission | 3 | 0 | 1 | 2 | 6 (38) |
Microbiology | Â | Â | Â | Â | Â |
   Gram-negative | 1 | 0 | 2 | 1 | 4 (25) |
   Gram-positive | 1 | 2 | 1 | 0 | 4 (25) |
   Other | 0 | 1 | 0 | 2 | 3 (19) |
   No pathogen detected | 2 | 1 | 1 | 1 | 5 (31) |
Blood culture-positive | 0 | 0 | 1 | 1 | 2 (12) |